Stratification of responders towards eculizumab using a structural epitope mapping strategy

Anna-Luisa Volk, Francis Jingxin Hu, Magnus M. Berglund, Erik Nordling, Patrik Strömberg, Mathias Uhlén, Johan Rockberg

Research output: Contribution to journalJournal articleResearchpeer-review

342 Downloads (Pure)


The complement component 5 (C5)-binding antibody eculizumab is used to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS). As recently reported there is a need for a precise classification of eculizumab responsive patients to allow for a safe and cost-effective treatment. To allow for such stratification, knowledge of the precise binding site of the drug on its target is crucial. Using a structural epitope mapping strategy based on bacterial surface display, flow cytometric sorting and validation via haemolytic activity testing, we identified six residues essential for binding of eculizumab to C5. This epitope co-localizes with the contact area recently identified by crystallography and includes positions in C5 mutated in non-responders. The identified epitope also includes residue W917, which is unique for human C5 and explains the observed lack of cross-reactivity for eculizumab with other primates. We could demonstrate that Ornithodorus moubata complement inhibitor (OmCI), in contrast to eculizumab, maintained anti-haemolytic function for mutations in any of the six epitope residues, thus representing a possible alternative treatment for patients non-responsive to eculizumab. The method for stratification of patients described here allows for precision medicine and should be applicable to several other diseases and therapeutics.
Original languageEnglish
Article number31365
JournalScientific Reports
Number of pages10
Publication statusPublished - 2016

Bibliographical note

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit


  • Immunotherapy
  • Molecular biology
  • Molecular medicine


Dive into the research topics of 'Stratification of responders towards eculizumab using a structural epitope mapping strategy'. Together they form a unique fingerprint.

Cite this